Anlotinib
- Generic Name
- Anlotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
Safety and Efficacy of Amlotinib in the Treatment of Recurrent Craniopharyngioma
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 57
- Registration Number
- NCT06970145
- Locations
- 🇨🇳
Southern Medical University, Nanfang Hospital, Department of Neurosurgery, Guangzhou, Guangdong, China
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Phase 4
Not yet recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 31
- Registration Number
- NCT06951841
- Locations
- 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Phase 4
Not yet recruiting
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06931145
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Phase 2
Recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 47
- Registration Number
- NCT06851247
- Locations
- 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Phase 2
Not yet recruiting
- Conditions
- Solid TumorsChildrenAdolescents
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-08
- Target Recruit Count
- 49
- Registration Number
- NCT06761417
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Phase 2
Recruiting
- Conditions
- Solid TumorPrecision Medicine
- Interventions
- Drug: Target GeneDrug: Sacituzumab Govitecan-Hziy 180 MGDrug: PD-1/PD-L1/PD-1&CTLA4 inhibitor
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06739395
- Locations
- 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
Phase 2
Not yet recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaNeoadjuvant TherapyPD-L1Anlotinib
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Target Recruit Count
- 45
- Registration Number
- NCT06699498
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Phase 1
Not yet recruiting
- Conditions
- OsteosarcomaSoft Tissue Sarcoma (STS)
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 448
- Registration Number
- NCT06699576
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 40
- Registration Number
- NCT06678230
- Locations
- 🇨🇳
Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China, Changchun, Jilin, China
Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients
Phase 2
Not yet recruiting
- Conditions
- Advanced Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 56
- Registration Number
- NCT06662006
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath